Arbutus Biopharma CorporationABUSNASDAQ
LOADING
|||
Revenue Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year revenue growth rate
Latest
-95.07%
↓ 285% below average
Average (39q)
51.51%
Historical baseline
Range
High:563.33%
Low:-125.19%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -95.07% |
| Q2 2025 | 508.79% |
| Q1 2025 | 12.07% |
| Q4 2024 | 17.55% |
| Q3 2024 | -22.42% |
| Q2 2024 | 12.66% |
| Q1 2024 | -28.58% |
| Q4 2023 | -53.95% |
| Q3 2023 | 0.15% |
| Q2 2023 | -30.45% |
| Q1 2023 | 7.08% |
| Q4 2022 | 4.92% |
| Q3 2022 | -58.21% |
| Q2 2022 | 13.19% |
| Q1 2022 | 292.42% |
| Q4 2021 | -4.01% |
| Q3 2021 | 43.41% |
| Q2 2021 | 10.22% |
| Q1 2021 | -11.44% |
| Q4 2020 | 56.66% |
| Q3 2020 | 0.59% |
| Q2 2020 | 1.54% |
| Q1 2020 | -7.85% |
| Q4 2019 | -47.14% |
| Q3 2019 | 368.76% |
| Q2 2019 | -3.83% |
| Q1 2019 | -59.54% |
| Q4 2018 | 5.73% |
| Q3 2018 | 27.57% |
| Q2 2018 | -13.37% |
| Q1 2018 | -43.33% |
| Q4 2017 | -63.23% |
| Q3 2017 | 563.33% |
| Q2 2017 | 342.13% |
| Q1 2017 | 220.51% |
| Q4 2016 | -125.19% |
| Q3 2016 | 150.49% |
| Q2 2016 | -48.76% |
| Q1 2016 | -95.25% |
| Q4 2015 | 212.08% |